TRUH - ETF AI Analysis
Top Page
VanEck Healthcare TruSector ETF (TRUH)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered strong gains so far this year and over the past three months, showing solid recent momentum.
Leading Healthcare Companies
Several of the largest holdings, such as Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth, and Merck, have shown strong performance, helping drive the fund’s returns.
Low Expense Ratio
The fund’s relatively low fee means more of any gains can stay in investors’ pockets instead of going to costs.
Negative Factors
Single-Sector Concentration
The ETF is fully focused on the healthcare sector, so it may be more affected by downturns or policy changes that hit this industry specifically.
U.S.-Only Exposure
All of the fund’s holdings are in U.S. companies, which limits diversification across different global markets.
Mixed Performance Among Top Holdings
Some key positions like Thermo Fisher, Abbott Laboratories, and Pfizer have shown weaker or negative performance, which can offset gains from stronger stocks.
TRUH vs. SPDR S&P 500 ETF (SPY)
AUM598.38K
RegionNorth America
Expense Ratio0.10%
Beta-0.53
IssuerVanEck
Inception DateApr 01, 2026
Dividend Yield0.29%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume913
30 Day Avg. Volume884
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
31.78Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering59
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TRUH Summary
VanEck Healthcare TruSector ETF (TRUH) is a U.S. health care fund that invests in drug makers, biotech firms, medical device companies, and health insurers instead of tracking a single index. A team of managers actively picks and adjusts holdings, with well-known names like Eli Lilly and Johnson & Johnson among its top positions. Investors might consider TRUH if they want focused exposure to the long-term growth of medical innovation and the steady demand for health services. However, because it is concentrated in health care and actively managed, its price can move up and down more than a broad market fund.
How much will it cost me?This ETF has an expense ratio of 0.10%, which means you’ll pay about $1 per year for every $1,000 you invest. That’s lower than the average ETF because, despite being actively managed, it’s priced more like a low-cost fund, helping keep your ongoing costs relatively small.
What would affect this ETF?This U.S. health care ETF could benefit if medical innovation, an aging population, and steady demand for drugs, devices, and health services support growth at major holdings like Eli Lilly, Johnson & Johnson, and UnitedHealth, especially if the economy slows and investors favor more defensive sectors. On the other hand, tighter drug pricing rules, changes to government health programs, or weaker results from big pharmaceutical and biotech companies could hurt returns, and its focus on a single U.S. sector means it may be more volatile than a broadly diversified fund.
TRUH Top 10 Holdings
This ETF is a pure play on U.S. health care, and its story is being written mostly by a few heavyweight drugmakers. Eli Lilly sits in the driver’s seat but has cooled off recently, so it’s not pulling the fund as hard as before. Johnson & Johnson, AbbVie, and Merck are doing more of the heavy lifting, with steady-to-rising trends that support overall performance. UnitedHealth adds a managed-care twist with mixed signals, while Thermo Fisher and Abbott are more of a tug-of-war, with recent wobbling tempering the sector’s otherwise solid momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 15.53% | $132.12K | $1.08T | 45.82% | 72 Outperform | |
| Johnson & Johnson | 10.55% | $89.72K | $617.78B | 48.74% | 78 Outperform | |
| AbbVie | 7.58% | $64.49K | $443.36B | 24.30% | 66 Neutral | |
| UnitedHealth | 6.43% | $54.70K | $376.34B | 72.36% | 72 Outperform | |
| Merck & Company | 5.50% | $46.74K | $321.57B | 59.99% | 80 Outperform | |
| Thermo Fisher | 3.65% | $31.01K | $213.42B | 23.03% | 72 Outperform | |
| Amgen | 3.53% | $30.04K | $207.87B | 25.48% | 77 Outperform | |
| Abbott Laboratories | 3.14% | $26.74K | $182.90B | -17.56% | 73 Outperform | |
| Gilead Sciences | 2.77% | $23.57K | $161.66B | 14.53% | 78 Outperform | |
| Pfizer | 2.44% | $20.73K | $142.54B | 6.37% | 74 Outperform |
TRUH Technical Analysis
Positive
―
Price Trends
27.34
Positive
Market Momentum
0.31
Positive
53.96
Neutral
29.76
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TRUH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 28.22, equal to the 50-day MA of 27.34, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.31 indicates Positive momentum. The RSI at 53.96 is Neutral, neither overbought nor oversold. The STOCH value of 29.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TRUH.
TRUH Peer Comparison
Comparison Results
Performance Comparison
TRUH
VanEck Healthcare TruSector ETF
28.27
2.86
11.26%
PSR
Invesco Active U.S. Real Estate Fund
―
―
―
REIT
ALPS Active REIT ETF
―
―
―
GABF
Gabelli Financial Services Opportunities ETF
―
―
―
SEMI
Columbia Seligman Semiconductor and Technology ETF
―
―
―
BESF
Bastion Energy ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents